We are excited to announce that Ethiqa XR® is now available from MWI Animal Health, Covetrus, and Midwest Veterinary Supply. Contact MWI Animal Health, Covetrus, or Midwest Veterinary Supply to place your order.
Ethiqa XR should be handled carefully to minimize the risk of diversion, including restriction of access, the use of accounting procedures, and proper disposal methods, as appropriate to the laboratory setting and as required by law.
|Packaging||Multi-dose vial of 3 mL of injectable suspension|
|Buprenorphine concentration||1.3 mg/mL|
|Dosing—Mice||Single subcutaneous injection of 0.05 mL per 20-gram mouse (3.25 mg/kg body weight)|
|Dosing—Rats||Single subcutaneous injection of 0.1 mL per 200-gram rat (0.65 mg/kg body weight)|
|Dose Repetition||If needed, a single repeat dose may be administered after the initial dose|
|Syringe/Needle Size||Use a 0.5- or 1.0-mL syringe fitted with a 20- to 23-gauge needle for injections|
|Stability||Approved for 12-month shelf life|
|Storage||Store vial at 15° to 25°C (59° to 77°F) or refrigerated. Do not freeze. Store in a locked, substantially constructed cabinet according to DEA and local controlled substance guidelines|
|Administration||Ethiqa XR should only be handled and administered by a veterinarian, veterinary technician or laboratory staff trained in the handling of potent opioids|
Important Safety Information for Rats and Mice, Not for use in humans
For Rats and Mice:
Only administer Ethiqa XR by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use on mice or rats with pre-existing respiratory deficiencies. Do not keep rats on wood chip-type bedding after administration of Ethiqa XR. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression.
Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids. Protective clothing is recommended to avoid direct contact with human skin or mucus membranes which could result in absorption of buprenorphine and adverse reactions. Not for use in humans.
For more information, consult the prescribing information including the boxed warning.